Sponsored Links 
Sepracor Inc.
Company Description
Sepracor develops safer, purer, and more effective drugs to improve on already existing pharmaceuticals. The company develops compounds to improve a therapy's efficacy, side-effects, or both.
Crushed Estimates
On Jul 24 Sepracor reported second-quarter results that included an 11% pop in revenue, up to $326 million. Earnings per share came in at 72 cents, almost double the Zacks Consensus Estimate of 38 cents.
This was the third consecutive surprise.
Raising Guidance
Management went on to raise full-year guidance, increasing estimated revenue to $1.25 billion, give or take $25 million. Earnings per share are expected to be between $2.55 and $2.90, up from between $2.10 and $2.70.
Estimtes Follow
After the release, the Zacks consensus estimate spiked to $2.88, from $2.41, for full-year 2009. This would be a year-over-year growth rate of 80%.
Analysts polled by Zacks also raised estimates for next year, which now average $2.90, up from $2.63.
Good Value
Share of SEPR are trading at 7 times earnings and with a PEG ratio of just 0.4. The average PEG ratio for its peers is a loft 2.6 times.
The Chart
SEPR has been on a great run over the past couple months of setting higher highs and higher lows. This is a great bullish trend hear. Take a look below.
 |
 |
 Share |
 RSS |
 Rate Pos |
 Rate Neg |
 Comment |
|
|
||||||
Loading Stories...- Free Four Zacks #1 Rank "Strong Buy" Stocks
- Free Timely Market Commentary
- Free Wealth Management Tips
- Free Profitable Strategy Screens
- Free Bull and Bear Stocks of the Day
Loading Stories...Most Popular on Zacks.com
More Zacks Resources
More Zacks Links
| Market Summary | Feb 10, 2010 01:10 am ET |
150.25
0.00
[CLICK TO CLOSE X]
days
ago
[CLICK TO CLOSE X]
days
ago
[CLICK TO CLOSE X]